HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour.

Abstract
This retrospective study describes three clinically different groups of patients with symptomatic androgen-independent prostate cancer (AIPC) referred to palliative radiotherapy (RT): those with a symptomatic pelvic tumour and pelvis-confined disease (M0 P-RT: 35 patients), those with a symptomatic pelvic tumour and distant metastases (M + P-RT: 97 patients) and those with painful bone metastases (BM-RT: 193 patients). The study emphasises the need of a combined surgical and radiotherapeutic palliation in AIPC patients with symptomatic pelvic tumours. Median overall survival from time of palliative RT was 19, 9 and 8 months for M0 P-RT, M + P-RT and BM-RT patients, respectively (p < 0.001). The significantly prolonged natural course of P-RT patients without distant metastases has to be accounted for in clinical trials of AIPC patients in whom survival represents an endpoint. Furthermore, the optimal palliation regimens for P-RT patients are still to be defined.
AuthorsEivor Hernes, Sophie D Fosså, Eva Skovlund
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 42 Issue 7 Pg. 749-55 ( 2003) ISSN: 0284-186X [Print] England
PMID14690161 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
Topics
  • Aged
  • Androgen Antagonists (therapeutic use)
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Bone Neoplasms (radiotherapy, secondary)
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Middle Aged
  • Palliative Care
  • Pelvic Neoplasms (radiotherapy, secondary)
  • Prostatic Neoplasms (pathology, radiotherapy, surgery)
  • Retrospective Studies
  • Survival Analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: